Women: induction of ovulation in infertility due to the lack of ovulation or impaired maturation of the follicles; monitored ovarian hyperstimulation to obtain egg cells for in vitro fertilization; prevention of corpus luteum failure. Men: hypoganadotropic hypogonadism; delayed maturation associated with pituitary gonadotropic insufficiency; cryptorchidism not due to an anatomical reason.
Composition:
1 amp. contains 5000 IU chorionic gonadotropin.
Action:
Human hCG placental gonadotropin with luteinizing hormone (LH) activity. LH is necessary for the normal development and maturation of male and female gametes and the production of steroids by the gonads. In women, the product is administered mid-cycle as a substitute for endogenous LH to stimulate the final phase of ovarian follicles, leading to ovulation; the preparation is also given as a substitute for endogenous LH in the luteal phase. In men, the preparation is given to stimulate Leydig cells to stimulate testosterone production. The highest concentration of hCG in plasma is achieved in men after about 6 hours and 16 hours after a single hCG administration, respectively intramuscularly or subcutaneously, and in women after about 20 hours.0,5 is about 33 hours.
Contraindications:
Hypersensitivity to the components of the preparation. Suspected existence or existence of hormone-dependent cancers such as ovarian, breast and cervical cancer in women and prostate cancer or mammary gland in men. Genital defects that prevent pregnancy. Uterine fibroids preventing pregnancy.
Precautions:
Before starting treatment, exclude endocrine disorders not related to gonads, min. thyroid, adrenal or pituitary disorders. Women: if you experience undesirable ovarian hyperstimulation, discontinue the use of FSH containing preparation, avoid becoming pregnant and not give hCG (this warning is especially important in patients with polycystic ovary syndrome); due to the increased risk of thromboembolic events, the risk and benefits of extracorporeal fertilization should be considered in patients with a history or family history of thromboembolism, significant obesity (WMC> 30 kg / m2) or thrombophilia. Males: patients with latent or overt cardiac failure, impaired renal function. hypertension, epilepsy or migraine (also in history) should remain under constant medical supervision (sometimes increased androgen production accompanying treatment may lead to worsening of the current clinical condition or recurrence of the disease); for boys prior to puberty, hCG should be administered with caution to avoid premature calcification of the bone growth cartilage or the occurrence of precocious puberty (bone system should be monitored regularly). The preparation should not be used to reduce body weight. HCG has no effect on fat metabolism, fat distribution or appetite.
Pregnancy and lactation:
Do not use the preparation during pregnancy and breast-feeding.
Side effects:
A general rash or fever may rarely occur. Injection site reactions such as bruising, pain, redness, swelling and itching may occur. Occasionally, allergic reactions were reported most frequently as pain and / or a rash at the injection site. In women: in rare cases, thromboembolic disorders associated with FSH / hCG therapy, usually combined with severe ovarian hyperstimulation syndrome (OHSS), pleural effusion as a complication of severe OHSS, abdominal pain, gastrointestinal symptoms like nausea and diarrhea associated with benign OHSS , ascites, as a complication of severe OHSS, unwanted ovarian hyperstimulation, mild or severe ovarian hyperstimulation syndrome, breast pain, mild to moderate ovarian enlargement and ovarian cysts associated with benign ovarian hyperstimulation syndrome, large ovarian cysts (prone to rupture), usually associated with severe OHSSweight gain as characteristic of severe ovarian hyperstimulation syndrome. In men: water and sodium retention was observed occasionally after administration of high doses (this is associated with increased androgen production), occasionally gynecomastia.
Dosage:
Intramuscularly or subcutaneously.Women. Induction of ovulation in infertility due to lack of ovulation or impaired maturation of follicles: usually one injection of 5000 to 10,000 IU. after treatment with the FSH containing formulation. Monitored ovarian hyperstimulation to obtain oocytes for in vitro fertilization: usually one 5,000 to 10,000 IU injection. after treatment with the FSH containing formulation. Prevention of corpus luteum failure: 2-3 repeated injections at a dose of 1000 to 3000 IU. each, within 9 days after the onset of ovulation or embryo transfer (eg on days 3, 6 and 9 after ovulation induction).Men. Hypogonadotropic hypogonadism: 1,000-2000 IU 2-3 times per week. In the case of reduced fertility, the drug can be administered additionally with the FSH containing formulation 2-3 times a week, in order to obtain an improvement in spermatogenesis, treatment should be continued for at least 3 months. During this therapy, supplementary therapy with testosterone should not be used. The therapeutic effect obtained can be maintained while Preginyl is used alone. Delayed maturation associated with pituitary gonadotropic insufficiency: 1500 IU 2-3 times a week, for at least 6 months. Cryptorconia, not due to an anatomical reason: over 6 years of age: 1,500 IU 2 times a week for 6 months, less than 6 years: 500-1000 IU 2 times a week for 6 months, less than 2 years - 250 IU 2 times a week for 6 months; if necessary, treatment can be repeated.
(C)
